Growth Metrics

Incyte (INCY) Total Non-Current Liabilities (2013 - 2026)

Incyte posted quarterly Total Non-Current Liabilities of $1.6 billion for Q1 2026, down 16.61% year-on-year from $1.9 billion in Q1 2025, and down 2.19% on a QoQ basis from $1.6 billion in Q4 2025.

Incyte (INCY) has 14 years of Total Non-Current Liabilities data on file, last reported at $1.6 billion in Q1 2026.

  • For the quarter ending Q1 2026, Total Non-Current Liabilities fell 16.61% year-over-year to $1.6 billion; the trailing twelve-month figure through Mar 2026 stood at $1.6 billion (down 16.61% YoY), and the FY2025 full-year result was $1.6 billion, down 11.15% from the prior year.
  • Total Non-Current Liabilities for Q1 2026 stood at $1.6 billion, down from $1.6 billion in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $1.9 billion in Q1 2025 and bottomed at $1.1 billion in Q3 2022.
  • The 5-year median for Total Non-Current Liabilities is $1.5 billion (2025), against an average of $1.5 billion.
  • The widest annual swing landed in 2022, when Total Non-Current Liabilities surged 54.44%; it then slipped 16.61% in 2026.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $1.3 billion in 2022, then rose by 12.18% to $1.4 billion in 2023, then grew by 26.75% to $1.8 billion in 2024, then slipped by 11.15% to $1.6 billion in 2025, then decreased by 2.19% to $1.6 billion in 2026.
  • The last three Total Non-Current Liabilities figures came in at $1.6 billion (Q1 2026), $1.6 billion (Q4 2025), and $1.5 billion (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn - 11.03 Mn
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn - 42,980.09
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn 95.20 Mn
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn - 110.28 Mn
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn - -
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn 5.87 Bn
7 Evaxion A 64.16 Bn 64.14 Bn - -
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn 7.32 Bn
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn 4.05 Bn
10 Incyte 19.28 Bn 15.27 Bn 1.17 Bn 1.59 Bn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 1.59 Bn
Dec 31, 2025 1.63 Bn
Sep 30, 2025 1.51 Bn
Jun 30, 2025 1.47 Bn
Mar 31, 2025 1.91 Bn
Dec 31, 2024 1.83 Bn
Sep 30, 2024 1.70 Bn
Jun 30, 2024 1.52 Bn
Mar 31, 2024 1.58 Bn
Dec 31, 2023 1.44 Bn
Sep 30, 2023 1.32 Bn
Jun 30, 2023 1.29 Bn
Mar 31, 2023 1.22 Bn
Dec 31, 2022 1.29 Bn
Sep 30, 2022 1.11 Bn
Jun 30, 2022 1.16 Bn
Mar 31, 2022 1.12 Bn
Dec 31, 2021 1.09 Bn
Sep 30, 2021 987.87 Mn
Jun 30, 2021 749.75 Mn
Mar 31, 2021 879.13 Mn
Dec 31, 2020 722.05 Mn
Sep 30, 2020 683.65 Mn
Jun 30, 2020 631.23 Mn
Mar 31, 2020 574.84 Mn
Dec 31, 2019 585.39 Mn
Sep 30, 2019 219.80 Mn
Jun 30, 2019 450.37 Mn
Mar 31, 2019 415.83 Mn
Dec 31, 2018 203.00 Mn
Sep 30, 2018 203.70 Mn
Jun 30, 2018 405.74 Mn
Mar 31, 2018 656.71 Mn
Dec 31, 2017 157.80 Mn
Sep 30, 2017 356.88 Mn
Jun 30, 2017 599.81 Mn
Mar 31, 2017 628.79 Mn
Dec 31, 2016 1.21 Bn
Sep 30, 2016 161.00 Mn
Jun 30, 2016 844.60 Mn
Mar 31, 2016 827.96 Mn
Dec 31, 2015 787.90 Mn
Sep 30, 2015 137.30 Mn
Jun 30, 2015 823.31 Mn
Mar 31, 2015 851.13 Mn
Dec 31, 2014 823.55 Mn
Sep 30, 2014 822.47 Mn
Jun 30, 2014 805.70 Mn
Mar 31, 2014 795.21 Mn
Dec 31, 2013 795.87 Mn
Sep 30, 2013 325.22 Mn
Jun 30, 2013 358.57 Mn